Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: The HORIZON-Pivotal Fracture Trial (PFT)

导出原文传递

翻译打印收藏纠错

作者： Jacques,R.M. ^[1] ; Boonen,S. ^[2] ; Cosman,F. ^[3] ; Reid,I.R. ^[4] ; Bauer,D.C. ^[5] ; Black,D.M. ^[6] ; Eastell,R.

作者单位： Division of Geriatric Medicine, Leuven University, Leuven, Belgium ^[1] School of Health and Related Research, University of Sheffield, Sheffield, United Kingdom ^[2] Department of Medicine, University of Auckland, Auckland, New Zealand ^[3] Sheffield National Institute for Health Research Bone Biomedical Research Unit, University of ^[4] Regional Bone Center, Helen Hayes Hospital, West Haverstraw, NY, United States ^[5] Department of Epidemiology and Biostatistics, University of California, San Francisco, San ^[6]

关键词 BONE MINERAL DENSITY FRACTURE PERCENT OF TREATMENT EFFECT EXPLAINED PINP SURROGATE ZOLEDRONIC ACID

发布时间 2013-11-20

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交